ADH4 and metabolic dysfunction-associated steatotic liver disease: Treatment with gemcabene reduced the mRNA expression levels of metabolic genes linked to lipogenesis and lipid modulation, such as ACC1, ApoC-III and ADH-4, likely causal targets for the treatment of NAFLD and targets for molecules currently in clinical development.